| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| Do | Alpha Tau Medical Ltd.: Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange | 1 | GlobeNewswire (USA) | ||
| 22.10. | Alpha Tau Medical Ltd.: Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT for Pancreatic Cancer Patients in Korea | 3 | GlobeNewswire (USA) | ||
| 21.10. | H.C. Wainwright bekräftigt Kaufempfehlung für Alpha Tau Medical nach Ausweitung der klinischen Studie | 1 | Investing.com Deutsch | ||
| 19.10. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| ALPHA TAU MEDICAL Aktie jetzt für 0€ handeln | |||||
| 19.10. | FDA genehmigt Ausweitung der Glioblastom-Studie von Alpha Tau auf 20 Patienten | 3 | Investing.com Deutsch | ||
| 19.10. | FDA expands Alpha Tau glioblastoma trial to 20 patients | 2 | Investing.com | ||
| 19.10. | Alpha Tau Medical Ltd.: Alpha Tau Announces FDA Approval to Expand Alpha DaRT U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 23.09. | XFRA NEW INSTRUMENTS AVAILABLE ON 23.09.2026 | 579 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.09.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.09.2026
Aktien
1 US4618651073 Iochpe-Maxion S.A. ADR
2... ► Artikel lesen | |
| 01.09. | H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment | 2 | Investing.com | ||
| 31.08. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 12 | SEC Filings | ||
| 12.08. | H.C. Wainwright raises Alpha Tau Medical stock price target to $16 | 1 | Investing.com | ||
| 12.08. | H.C. Wainwright hebt Kursziel für Alpha Tau Medical auf 16 $ an | 3 | Investing.com Deutsch | ||
| 10.08. | Alpha Tau Medical GAAP EPS of -$0.25 | 1 | Seeking Alpha | ||
| 10.08. | Alpha Tau Medical Ltd.: Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update | 437 | GlobeNewswire (Europe) | - Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial... ► Artikel lesen | |
| 10.08. | Alpha Tau plans dual listing on Nasdaq and TASE to expand access for Israeli investors | 4 | Seeking Alpha | ||
| 10.08. | Alpha Tau Medical Ltd.: Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) | 1 | GlobeNewswire (USA) | ||
| 10.08. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.07. | H.C. Wainwright reiterates Alpha Tau Medical stock rating at buy | 1 | Investing.com | ||
| 21.07. | Alpha Tau rises on Alpha DaRT head and neck cancer data | 5 | Seeking Alpha |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NYXOAH | 0,732 | -0,14 % | XFRA 5YI: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| INSILICO MEDICINE | 4,200 | +0,48 % | INSILICO (03696): DISCLOSEABLE TRANSACTION PARTICIPATION IN THE ESTABLISHMENT OF AN INVESTMENT FUND | ||
| TACTILE SYSTEMS TECHNOLOGY | 22,420 | +0,99 % | Tactile Medical targets $50M-$52M adjusted EBITDA in 2026 while maintaining $360M-$366M revenue outlook | ||
| BRIGHTSPRING HEALTH SERVICES | 69,84 | 0,00 % | Guggenheim raises BrightSpring Health stock price target on growth | ||
| FRESENIUS MEDICAL CARE | 39,040 | -3,60 % | UBS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Sell' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für FMC mit einem Kursziel von 36 Euro auf "Sell" belassen. Der Gegenwind für die Gewinnentwicklung im Jahr 2027 nehme zu, schrieb... ► Artikel lesen | |
| FRESENIUS | 48,810 | +0,47 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - JPMorgan hat Fresenius mit einem Kursziel von 55,20 Euro auf "Overweight" belassen. Die Aktie steht zudem auf der "Analyst Focus List" der US-Bank. Die Anlagestory des... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,350 | -0,12 % | dpa-AFX-Überblick: UNTERNEHMEN vom 28.10.2026 - 15.15 Uhr | ROUNDUP: UBS enttäuscht trotz Gewinnplus mit Vermögensverwaltung - Kursrutsch ZÜRICH - Die Schweizer Großbank UBS hat im dritten Quartal Erträge und Gewinn gesteigert. Zudem befindet sie sich bei... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 20,170 | 0,00 % | PROCEPT BioRobotics to Report Third Quarter 2026 Financial Results on November 4th, 2026 | ||
| BILLIONTOONE | 110,45 | 0,00 % | BillionToOne, Inc.: BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds | MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| HEARTFLOW | 54,37 | -0,06 % | Heartflow, Inc.: TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients | ||
| ADAPTHEALTH | 6,300 | +0,32 % | AdaptHealth Corp. - 10-Q, Quarterly Report | ||
| ALIGNMENT HEALTHCARE | 7,400 | +0,14 % | Alignment Healthcare lowers 2026 outlook as it navigates cost headwinds | ||
| LIFESTANCE HEALTH GROUP | 13,380 | +0,07 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 35,000 | +0,46 % | Carl Zeiss Meditec, Drägerwerk und Sartorius: Drägerwerk führt, Sartorius folgt, Carl Zeiss Meditec hängt zurück | ||
| GENEDX | 68,69 | +0,07 % | GeneDx plans to add long-read genome sequencing to portfolio |